Prot# CC-5013-CLL-009: A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid ®) Dose Regimens in Subjects with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date5/14/1011/1/17

Funding

  • INC Research, LLC (CC-5013-CLL-009)
  • Celgene Corporation (CC-5013-CLL-009)